A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Banner Health MD Anderson Phoenix, Gilbert, Arizona, United States

Dignity Health Cancer Institute, Phoenix, Arizona, United States

Alliance Dermatology, Phoenix, Arizona, United States

UCLA, Los Angeles, California, United States

Day Star Skin and Cancer Center, DeLand, Florida, United States

Integrity Research Clinical Associates, Delray Beach, Florida, United States

Palm beach Dermatology Group, Delray Beach, Florida, United States

Hollywood Dermatology, Hollywood, Florida, United States

University of Miami, Miami, Florida, United States

Baptist Health South Florida MCI, Miami, Florida, United States

Moffitt Cancer Center, Tampa, Florida, United States

Beer Dermatology, West Palm Beach, Florida, United States

Emory University, Atlanta, Georgia, United States

Mayo Clinic Rochester, Rochester, Minnesota, United States

Schweiger Dermatology Group, Hackensack, New Jersey, United States

New Mexico Cancer Center, Albuquerque, New Mexico, United States

Bassett Healthcare Network, Cooperstown, New York, United States

Northwell Health, Queens, New York, United States

New York Medical Skin Solutions, Rockaway Park, New York, United States

MDCS Dermatology, Smithtown, New York, United States

West Cancer Center, Germantown, Tennessee, United States

Gulf Coast Cancer Center, Houston, Texas, United States

University Cancer & Diagnostic Center, Houston, Texas, United States

University of Virginia Health System, Charlottesville, Virginia, United States

Dermatology of Seattle and Bellevue, Bellevue, Washington, United States

Princess Margaret Cancer Center, Toronto, Ontario, Canada

Rambam Medical Center, Haifa, Israel

Hadassah Medical Center, Jerusalem, Israel

Belinson-Rabin Medical Center, Petah Tikva, Israel

Sheba Medical Center, Ramat Gan, Israel